Why the study?
The study evaluated whether adiponectin concentration is an indicator of heart disease and whether it correlates with diastolic cardiac dysfunction to serve as a diagnostic and risk stratification marker.
Can serum adiponectin levels serve as a diagnostic and risk stratification marker in patients with diastolic cardiac dysfunction and chronic ischaemic heart disease?
Can serum adiponectin levels serve as a diagnostic and risk stratification marker in patients with diastolic cardiac dysfunction and chronic ischaemic heart disease?
Adiponectin concentration may indicate heart disease; leaves open its added value for risk stratification in practice.
This study does not propose to elucidate how adiponectin secretion is regulated, but how its adiponectin concentration is an indicator of heart disease. About adiponectin, it is not known whether it is functionally an enzyme, or very likely a cytokine/chemokine/hormone, secreted by fat cells/adipocytes in the abdomen. Abdominal fat secretes 67 hormones, and all of which cause disease. For example, adiponectin generates diabetes and ischaemic heart disease via dyslipidemia. Based on clinical symptoms, electrocardiographic and echocardiographic parameters, a group of 208 patients with diastolic cardiac dysfunction with or without preserved systolic function, developed on a background of painful chronic ischaemic heart disease, stable angina on exertion, was constituted. The serum levels of adiponectin, total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides were measured. Using the identified values, it was appreciated whether adiponectin correlates with the type of any of the two conditions, so that it can be recognised as a diagnostic and risk stratification marker.
No takes yet. Share an insight, caveat, or question.
Dincă et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: